ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed

ADC Therapeutics SA

LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).
LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.
ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.
PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.
Cash runway expected into 2028; company continues to grow ZYNLONTA revenue.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.